GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tilray Brands Inc (NAS:TLRY) » Definitions » Altman Z-Score
中文

Tilray Brands (Tilray Brands) Altman Z-Score : 0.17 (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Tilray Brands Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 0.17 is in distress zone. This implies bankruptcy possibility in the next two years.

Tilray Brands has a Altman Z-Score of 0.17, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Tilray Brands's Altman Z-Score or its related term are showing as below:

TLRY' s Altman Z-Score Range Over the Past 10 Years
Min: -0.95   Med: 2.3   Max: 45.62
Current: 0.17

During the past 12 years, Tilray Brands's highest Altman Z-Score was 45.62. The lowest was -0.95. And the median was 2.30.


Tilray Brands Altman Z-Score Historical Data

The historical data trend for Tilray Brands's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tilray Brands Altman Z-Score Chart

Tilray Brands Annual Data
Trend Aug14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.26 1.87 2.76 1.16 -0.95

Tilray Brands Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.77 -0.95 -0.32 -0.78 0.11

Competitive Comparison of Tilray Brands's Altman Z-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tilray Brands's Altman Z-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Tilray Brands's Altman Z-Score falls into.



Tilray Brands Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Tilray Brands's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.0717+1.4*-0.624+3.3*-0.06+0.6*1.6374+1.0*0.1764
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Feb. 2024:
Total Assets was $4,212.9 Mil.
Total Current Assets was $631.2 Mil.
Total Current Liabilities was $329.1 Mil.
Retained Earnings was $-2,628.7 Mil.
Pre-Tax Income was -107.854 + -49.563 + -48.599 + -111.687 = $-317.7 Mil.
Interest Expense was -8.517 + -8.625 + -9.835 + -38.052 = $-65.0 Mil.
Revenue was 188.34 + 193.771 + 176.949 + 184.188 = $743.2 Mil.
Market Cap (Today) was $1,424.2 Mil.
Total Liabilities was $869.8 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(631.211 - 329.1)/4212.856
=0.0717

X2=Retained Earnings/Total Assets
=-2628.741/4212.856
=-0.624

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-317.703 - -65.029)/4212.856
=-0.06

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=1424.213/869.815
=1.6374

X5=Revenue/Total Assets
=743.248/4212.856
=0.1764

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Tilray Brands has a Altman Z-Score of 0.17 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Tilray Brands  (NAS:TLRY) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Tilray Brands Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Tilray Brands's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Tilray Brands (Tilray Brands) Business Description

Address
265 Talbot Street West, Leamington, ON, CAN, N8H 5L4
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.
Executives
Denise M Faltischek officer: Chief Strategy Officer C/O THE HAIN CELESTIAL GROUP, INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Mitchell Gendel officer: Global General Counsel EMERALD HOLDING, INC., 100 BROADWAY, 14TH FLOOR, NEW YORK NY 10005
Irwin D Simon director, officer: President & CEO C/O THE HAIN CELESTIAL GROUP INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Carl A Merton officer: Chief Financial Officer C/O TILRAY, INC., 745 FIFTH AVENUE, SUITE 1602, NEW YORK NY 10151
Brendan Kennedy director 1920 EASTLAKE AVENUE E., SEATTLE WA 98105
James R. Meiers officer: Head of Canada C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David G. Hopkinson director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Thomas P. Looney director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Johann Michael Herhalt director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Jodi L. Butts director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David F Clanachan director TIM HORTONS INC., 874 SINCLAIR ROAD, OAKVILLE A6 L6K 2Y1
Renah Persofsky director 55 PRINCE ARTHUR AVENUE, #604, TORONTO A6 M5R 1B3
Jon Edward Levin officer: Chief Operating Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Michael C. Kruteck officer: Chief Financial Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Rebekah Dopp director 444 LENOX AVENUE, SOUTH ORANGE NJ 07079